Osivax Secures EUR 10M Grant from Bpifrance to Support Clinical Development of OVX836, a Broad-Spectrum Influenza Vaccine
Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced that it has secured EUR 10M from
Source: finanznachrichten.de